ClinicalTrials.gg
CompletedNCT05991661Updated Mar 5, 2026

XKH001 Injection in Healthy Subjects

A Phase 1/2 interventional study of XKH001 Injection and XKH001 Placebo Injection in Asthma, sponsored by Beijing Kanova Biopharmaceutical Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Beijing Kanova Biopharmaceutical Co., LTD · Phase 1/2, Interventional, and Health services research

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
171st of 182
24 · median 203
Started
2023
with 22 others
Phase 1/2
4 of 251
2 open now
Registered
146th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 171st largest by enrollment of the 182 interventional ones that give a count, is one of 23 that started in 2023, is one of 4 in phase 1/2, and was the 146th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) clinical study. The primary objective is to evaluate the safety, tolerability, and PK of multiple SC doses of XKH001 in healthy subjects.

Read the detailed description

A total of 5 cohorts are planned, with 8 subjects (6 on XKH001 and 2 on placebo) in each cohort. The dosing schedule for the first 3 cohorts is as follows:

Cohort Dosing Regimen

  1. 100 mg Q4W (D1, D29, D57)
  2. 300 mg Q4W (D1, D29, D57)
  3. 600 mg Q4W (D1, D29, D57) After completion of a 6-week safety observation (D1\~D43) in the previous cohort, the safety data will be reviewed (blinded) by the investigator and the Sponsor to assess the safety and tolerability of the investigational product. If the dose regimen for the previous cohort is confirmed to be safe and tolerable, dose escalation will continue to the next cohort.

The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.

Healthy subjects will be screened within 7 days prior to the first dose and successfully screened subjects will be assigned to the currently ongoing cohort and randomized to receive XKH001 or placebo. Subjects will be admitted to the study site the day before each scheduled dose (D-1, or D28, or D56), complete necessary pre-dose safety assessments, receive SC injection of XKH001 or placebo on D1, or D29, or D57, respectively, and continue to undergo regular safety assessment procedures and other blood sampling (PK, PD, and ADA) after dosing.

Subjects will also undergo comprehensive safety assessments on D15, D43, D71, D85, D113, D141 and D169, including AEs/serious adverse events (SAEs), vital signs, physical examinations, laboratory tests (hematology, blood chemistry, coagulation, urinalysis), 12-lead ECG, etc. Safety data as of D43 will be used by the Sponsor and investigator to assess the safety and tolerability of the investigational product.

If a subject discontinues treatment prematurely, the "Early Withdrawal" visit and all procedures will be performed as on D169.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects who voluntarily sign a written form (ICF) and are able to complete the study as required by the protocol;
  2. Male or female subjects aged 18 to 65 years (inclusive);
  3. Subjects with between 18 and 28 kg/m2 (inclusive);
  4. Subjects with normal or abnormal but not results of vital signs, physical examinations, laboratory tests, 12-lead ECGs and ≤ 450 ms;
  5. Subjects who did not use any prescription or over-the-counter medications within two weeks prior to dosing;
  6. Subjects who agree to have no child-bearing plans and to voluntarily take effective measures during the study and within 6 months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Subjects with diseases that may affect the subject's participation in this study within 5 years as judged by the investigator: including but not limited to gastrointestinal, renal, liver, lung, neurological, blood, endocrine, tumor, metabolic, psychiatric or cardio-cerebrovascular diseases, etc.;
  3. Subjects with history of diseases, known family history of inherited immunodeficiency disorders, or recurrent infections suggestive of possible immunodeficiency;
  4. Subjects with active infections requiring hospitalization or IV antibiotic treatment within 3 months prior to dosing, or bacterial, viral and fungal infections with clinical symptoms within 1 week;
  5. Subjects with a history of active tuberculosis or subjects with active or latent tuberculosis infection at screening;
  6. Subjects with positive in 5 items of hepatitis B serology (if HBsAg is negative, HBcAb is positive, and HBsAb is negative, HBV DNA quantitative test is required to be performed [the subject will be excluded if the test result is positive]), positive antibody, treponema pallidum antibody, antigen/antibody;
  7. Subjects who plan to receive live or within 4 weeks prior to dosing or during the study;
  8. Subjects who have participated in clinical studies of any drug or device within 3 months or 5 half-lives of the product (whichever is longer) prior to dosing;
  9. Subjects who are allergic to the investigational product or any component of the formulation of the investigational product or have a history of allergy to protein drugs;
  10. Subjects who have consumed more than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine) within 6 weeks prior to screening or have taken alcoholic products 1 day before dosing;
  11. Subjects who have a history of abuse of other drugs within 5 years prior to screening, or who have a positive urine drug screen result;
  12. Subjects who have a smoking history (> 5 cigarettes/day) within 3 months prior to screening;
  13. Subjects who have blood donation or blood loss of more than 450 mL within 8 weeks prior to screening, or blood donation of more than 200 mL or blood loss of more than 300 mL within 1 month;
  14. Subjects with obstructed venous access or intolerance to venipuncture;
  15. Subjects who are considered inappropriate for the study by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    XKH001 Injection

    Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.

    Drug: XKH001 Injection

  • Placebo comparator
    XKH001 Placebo Injection

    Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.

    Drug: XKH001 Placebo Injection

Interventions

  • 100mg/ml,1ml/vial

    Also known as: XKH001

  • DrugXKH001 Placebo Injection

    1ml/vial

    Also known as: XKH001 Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs);

    Incidence of adverse events (AEs) and serious adverse events (SAEs);

    Time frame: From baseline to 24 weeks of follow-up

  2. laboratory tests 1

    general condition

    Time frame: From baseline to 24 weeks of follow-up

  3. laboratory tests 2

    skin and mucosa

    Time frame: From baseline to 24 weeks of follow-up

  4. laboratory tests 3

    lymph nodes

    Time frame: From baseline to 24 weeks of follow-up

  5. laboratory tests 4

    head

    Time frame: From baseline to 24 weeks of follow-up

  6. laboratory tests 5

    neck

    Time frame: From baseline to 24 weeks of follow-up

  7. laboratory tests 6

    chest

    Time frame: From baseline to 24 weeks of follow-up

  8. laboratory tests 7

    abdomen

    Time frame: From baseline to 24 weeks of follow-up

  9. laboratory tests 8

    spine/extremities

    Time frame: From baseline to 24 weeks of follow-up

  10. observation of injection site

    The specific time of observation of injection site reactions is 2 h (± 30 min) post-dose and 4 h (± 30 min) post-dose.

    Time frame: 2 h (± 30 min) post-dose and 4 h (± 30 min) post-dose

  11. Vital signs

    Vital signs include temperature, pulse, and blood pressure. Vital signs will be measured within 60 min before dosing, 2 h (± 30 min), 4 h (± 30 min) after dosing on each dosing day (D1, or D29, or D57); at other visits, vital signs should be measured once.

    Time frame: From baseline to 24 weeks of follow-up

  12. Hematology

    Hematology should include hemoglobin, red blood cell (RBC) count, mean corpuscular hemoglobin, mean corpuscular volume, platelet count, white blood cell (WBC) count, and absolute and percentage of NEUT, LYM, and EOS.

    Time frame: From baseline to 24 weeks of follow-up

  13. Blood chemistry

    Blood chemistry should include fasting glucose, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase, total bilirubin, direct bilirubin, indirect bilirubin, gamma-glutamyl transpeptidase, creatinine, urea, sodium, potassium, calcium, inorganic phosphorus, chloride, serum lipase, and serum amylase.

    Time frame: From baseline to 24 weeks of follow-up

  14. Hematology includes: activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT).

    Hematology includes: activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT).

    Time frame: From baseline to 24 weeks of follow-up

  15. Three items of thyroid function

    Three items of thyroid function should include: FT3, FT4 and TSH.

    Time frame: From baseline to 24 weeks of follow-up

  16. Urinalysis

    Urinalysis should include specific gravity, potential of hydrogen (pH), glucose, bilirubin, urobilinogen, protein, ketones, and occult blood.

    Time frame: From baseline to 24 weeks of follow-up

  17. 12-lead ECGs

    12-lead ECGs will be performed at screening, 60 min (± 10 min), 30 min (± 10 min), 15 min (± 10 min) pre-dose on D1, 4 h (± 30 min) post-dose on D1, 4 h (± 30 min) post-dose on D15, D28, and D29, 4 h (± 30 min) post-dose on D43, D56, and D57, and on D58 (approximately 24 h), D59 (approximately 48 h), D61 (approximately 96 h), D64 (approximately 168 h), D71 (approximately 336 h), D85 (approximately 672 h), D113 (approximately 1344 h), D141 (approximately 2016 h), and D169 (approximately 2688 h); before dosing on D1, 3 ECGs should be obtained each time, with an interval of 1-2 min. ECGs from D58 to D169 should be completed within 10 min before PK blood sampling at the current visit for 3 consecutive times, with an interval of approximately 1-2 min.

    Time frame: From baseline to 24 weeks of follow-up

  18. Infectious disease

    Infectious disease testing should include 5 items of hepatitis B serology (hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody), hepatitis C antibody, treponema pallidum antibody, and HIV antigen/antibody. If the subject is negative for HBsAg, positive for HBcAb, and negative for HBsAb, HBV DNA testing is also required.

    Time frame: From baseline to 24 weeks of follow-up

  19. Anteroposterior chest X-ray

    Anteroposterior chest X-ray obtained within 3 months before screening is acceptable, and abdominal color ultrasonography obtained within 1 month before screening is acceptable.

    Time frame: From baseline to 24 weeks of follow-up

  20. PK Cmax

    Cmax,ss(Maximum observed concentration)

    Time frame: From baseline to 24 weeks of follow-up

  21. PK Cmin

    Cmin,ss(Minimum observed concentration)

    Time frame: From baseline to 24 weeks of follow-up

  22. PK Cavg

    Cavg,ss(Mean observed concentration)

    Time frame: From baseline to 24 weeks of follow-up

  23. PK AUC0-inf

    AUC0-inf,ss(Area under the serum concentration-time curve from zero to infinity)

    Time frame: From baseline to 24 weeks of follow-up

  24. PK AUC0-t

    AUC0-t,ss(Area under the serum concentration-time curve from zero to t)

    Time frame: From baseline to 24 weeks of follow-up

  25. PK Tmax

    Tmax,ss(Time of observed)

    Time frame: From baseline to 24 weeks of follow-up

  26. PK t1/2

    t1/2,ss(Terminal half-life)

    Time frame: From baseline to 24 weeks of follow-up

  27. PK AUCtau

    area under the serum concentration-time curve at steady state (AUCtau)

    Time frame: From baseline to 24 weeks of follow-up

  28. PK %AUCex

    percentage of extrapolated area under the serum concentration-time curve from zero to infinity at steady state (%AUCex)

    Time frame: From baseline to 24 weeks of follow-up

  29. PK λz

    elimination rate constant of serum concentration in the terminal phase (λz,ss)

    Time frame: From baseline to 24 weeks of follow-up

  30. PK Rac

    drug accumulation ratio (Rac)

    Time frame: From baseline to 24 weeks of follow-up

  31. PK Vz

    volume of distribution at steady state (Vz,ss/F)

    Time frame: From baseline to 24 weeks of follow-up

  32. PK CL

    clearance at steady state (CLss/F)

    Time frame: From baseline to 24 weeks of follow-up

  33. PK MRT

    mean residence time (MRT)

    Time frame: From baseline to 24 weeks of follow-up

Secondary outcomes

  1. Total IgE;

    Total Immunoglobulin E(IgE);

    Time frame: From baseline to 24 weeks of follow-up

  2. EOS count in whole blood;

    Eosinophil(EOS) count in whole blood;

    Time frame: From baseline to 24 weeks of follow-up

  3. NEUT count in whole blood;

    Neutrophil(NEUT) count in whole blood;

    Time frame: From baseline to 24 weeks of follow-up

  4. Blood LYM count;

    Blood Lymphocyte(LYM) count;

    Time frame: From baseline to 24 weeks of follow-up

  5. Levels of IL-25-related cytokines in serum

    Levels of IL-25-related cytokines in serum (multiple cytokine panel includes: IL-25, TARC, IL-8, MIP1β, Eotaxin, CXCL1 (KC/GROα), Eotaxin-3);

    Time frame: From baseline to 24 weeks of follow-up

  6. ADA

    Incidence of anti-drug antibodies (ADAs).

    Time frame: From baseline to 24 weeks of follow-up

Other outcomes

  1. QT/QTc

    Relationship between multiple-dose serum concentrations and QTcF

    Time frame: From baseline to 24 weeks of follow-up

07

Study locations

1 site
  • The First Hospital of Jilin University Phase I Clinical Research Center
    Changchun, Jilin 130000, China
08

References and documents

Publications

  • Zhang H, Zheng W, Peng R, Wu D, Hu Y, Sun T, Gao L, Liu Y, Guo L, Ding Y, Liu L. First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers. Expert Opin Investig Drugs. 2025 Jan-Feb;34(1-2):81-87. doi: 10.1080/13543784.2025.2453162. Epub 2025 Jan 20. PubMed 39815604 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Feb 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 14, 2023
StartActual
May 12, 2023
Primary completionActual
Feb 20, 2024
CompletionActual
Mar 29, 2024
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05991661
Lead sponsor
Beijing Kanova Biopharmaceutical Co., LTD
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
May 12, 2023
Primary completion
Feb 20, 2024
Completion
Mar 29, 2024
Last update
Mar 5, 2026

Study contacts

Yanhua Ding
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XKH001

Start the discussion